Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 05, 2019

SELL
$2.87 - $5.92 $195,160 - $402,560
-68,000 Closed
0 $0
Q3 2018

Nov 16, 2018

BUY
$4.5 - $7.6 $81,000 - $136,800
18,000 Added 36.0%
68,000 $0
Q2 2018

Sep 06, 2018

BUY
$5.3 - $6.9 $265,000 - $345,000
50,000 New
50,000 $0

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Exane Asset Management Portfolio

Follow Exane Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Exane Asset Management with notifications on news.